Meeting
2014 ASCO Annual Meeting
Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).
Authors
Gordana Vlahovic
Duke University Medical Center, Durham, NC
Gordana Vlahovic , Gerald E. Archer , Denise Lally-Goss , Sharon Norman , Annick Desjardins , Katherine B. Peters , Tulika Ranjan , Jason Watts , Patrick Healy , James Emmett Herndon II, Henry S. Friedman , Allan H. Friedman , Darell D. Bigner , John Howard Sampson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
00626483
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3069)
DOI
10.1200/jco.2014.32.15_suppl.3069
Abstract #
3069
Poster Bd #
136
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Correlation of survival with tumor antigen expression in patients with newly diagnosed glioblastoma receiving a multi-epitope pulsed dendritic cell vaccine.
First Author: Surasak Phuphanich
Poster
2023 ASCO Annual Meeting
Final results of phase 2 trial of personal dendritic cell (DC) vaccines loaded with autologous tumor antigens (ATA) in newly diagnosed glioblastoma (GBM).
First Author: Daniela Annenelie Bota
Poster
2019 ASCO Annual Meeting
Interim results of a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM).
First Author: Andrew B. Lassman
Poster
2019 ASCO Annual Meeting
Oral DNA vaccination targeting VEGFR-2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma, a phase I/II study: NCT03750071.
First Author: Wolfgang Wick